Article in Antiviral therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors at 3 institutions in 1 country.
Julie K WischDepartment of Neurology, 7548Washington University in St Louis, St. Louis, MO, USA.ORCID 0000-0003-3624-2784
Sarah A CooleyDepartment of Neurology, 7548Washington University in St Louis, St. Louis, MO, USA.
Kevin E YarasheskiDivision of Endocrinology, Metabolism and Lipid Research, 7548Washington University in St Louis, St. Louis, MO, USA.ORCID 0000-0001-5436-2451
W Todd CadeDivision of Physical Therapy, School of Medicine, 3065Duke University, Durham, NC, USA.
Dominic N ReedsDepartment of Medicine and the Center for Human Nutrition, 7548Washington University in St Louis, St. Louis, MO, USA.
Brittany NelsonDepartment of Neurology, 7548Washington University in St Louis, St. Louis, MO, USA.
Ruth AlemuDanforth Campus, 7548Washington University in St Louis, St. Louis, MO, USA.
Tricia H BurdoDepartment of Microbiology, Immunology and Inflammation, Center for Neurovirology and Gene Editing, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Beau M AncesDepartment of Neurology, 7548Washington University in St Louis, St. Louis, MO, USA.
Washington University in St. Louis · USDuke University · USTemple University · US
Funding
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Brian N Finck · 1999 to 2026
$30.2M
WU P&FP30DK020579 · NIDDK · WASHINGTON UNIVERSITY · PI Jennifer Lynn Powers Carson · 2013 to 2026
$27.1M
TrainingP41GM103422 · NIGMS · WASHINGTON UNIVERSITY · PI YARASHESKI, KEVIN E · 2012 to 2019
$12.0M
Functional Imaging Reserve in NeuroHIV (FIRN)R01MH118031 · NIMH · WASHINGTON UNIVERSITY · PI ANCES, BEAU M · 2018 to 2023
$3.7M
Exercise Training to Improve Brain Health in Older HIV+ IndividualsR01NR015738 · NINR · WASHINGTON UNIVERSITY · PI ANCES, BEAU M · 2015 to 2019
$3.0M
Cannabis, HIV and Mental Processing Systems (CHAMPS)R01DA054009 · NIDA · WASHINGTON UNIVERSITY · PI ANCES, BEAU M, BURDO, TRICIA HELEN · 2021 to 2025
$3.0M
Frailty and Brain Integrity in Older HIV-infected IndividualsR01NR014449 · NINR · WASHINGTON UNIVERSITY · PI ANCES, BEAU M · 2013 to 2017
$2.4M
NEUROIMAGING AND NEUROBEHAVIORAL BASIS OF RISKY DECISION-MAKING IN ADOLESCENTSR01NR012907 · NINR · WASHINGTON UNIVERSITY · PI ANCES, BEAU M · 2011 to 2015
$1.9M
THE EFFECTS OF AGE AND HIGHLY ACTIVE ANTIRETROVIRAL THERAPY ON BRAIN FUNCTIONR01NR012657 · NINR · WASHINGTON UNIVERSITY · PI ANCES, BEAU M · 2010 to 2014
backgroundSubstantial body composition alterations have been reported after starting combined antiretroviral therapy (cART). We characterized a cohort of chronically infected and virologically suppressed (VL < 50 copies/ml) men (≥50 years old) living with HIV (MLWH) who were switched to integrase inhibitors (INSTI), and compared their body composition parameters and proinflammatory/endocrine profiles to age-matched MLWH on integrase inhibitor free (non-INSTI) regimens, taking into account neighborhood-level measures of socioeconomic status (SES). In addition, we used previously published HIV-seronegative men of the same age as controls.
methodsWe used dual energy X-ray absorptiometry to quantify body composition parameters, and measured plasma proinflammatory/endocrine markers in 56 MLWH. We compared body composition to a publicly available dataset of 450 HIV-seronegative men of similar age. Within the MLWH group, body composition and plasma proinflammatory/endocrine markers were compared between individuals on INSTI and non-INSTI regimens, accounting for SES.
resultsMen living with HIV tended to have a greater android/gynoid ratio compared to HIV-seronegative men (
conclusionsAmong cART-experienced MLWH, those receiving INSTI-containing regimens had modestly lower adiposity compared to non-INSTI MLWH, although these differences were explained by SES.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV. · full record | OpenQuestion